Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics reported its second quarter 2026 financial results, highlighting progress in its drug pipeline including favorable preclinical data for NMRA-215 with planned IND submission and Phase 1 study initiation by end of 2026. NMRA-511 and NMRA-898 programs targeting Alzheimer's agitation and schizophrenia are progressing towards clinic…